KOPS - Das Institutionelle Repositorium der Universität Konstanz

An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response

An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response

Zitieren

Dateien zu dieser Ressource

Dateien Größe Format Anzeige

Zu diesem Dokument gibt es keine Dateien.

ÖHLSCHLÄGER, Peter, Michaela PES, Wolfram OSEN, Matthias DÜRST, Achim SCHNEIDER, Lutz GISSMANN, Andreas M. KAUFMANN, 2006. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. In: Vaccine. 24(15), pp. 2880-2893. ISSN 0264-410X. Available under: doi: 10.1016/j.vaccine.2005.12.061

@article{Ohlschlager2006-04-05impro-17501, title={An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response}, year={2006}, doi={10.1016/j.vaccine.2005.12.061}, number={15}, volume={24}, issn={0264-410X}, journal={Vaccine}, pages={2880--2893}, author={Öhlschläger, Peter and Pes, Michaela and Osen, Wolfram and Dürst, Matthias and Schneider, Achim and Gissmann, Lutz and Kaufmann, Andreas M.}, note={Abbreviations: APCs, antigen presenting cells; B-LCLs, B-lymphoblastic cell line; cc, cervical cancer; CIN, cervical intraepithelial neoplasia; CpG, unmethylated cytidine phosphate guanosine motifs; CS, calf serum; CT, cardiotoxin; CTLs, cytotoxic T lymphocytes; C-X-X-C, Zn binding motifs; DCs, dendritic cells; E7SH, rearranged (“shuffled”=SH) gene of the E7WT; E7WT, E7-wildtype gene/antigen of Human Papillomavirus Type 16; HLA, human leukocyte antigen; hr-HPVs, high-risk human papillomaviruses; i.m., intramuscularly; nt, nucleotides; PBMC, peripheral blood mononuclear cell; pRB, retinoblastoma protein; s.c., subcutaneously; Th, T helper cells; VP22, herpes simplex virus VP22} }

<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/17501"> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2012-01-18T11:29:45Z</dcterms:available> <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/17501"/> <dc:creator>Pes, Michaela</dc:creator> <dc:contributor>Dürst, Matthias</dc:contributor> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2012-01-18T11:29:45Z</dc:date> <dc:rights>deposit-license</dc:rights> <dcterms:title>An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response</dcterms:title> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:contributor>Gissmann, Lutz</dc:contributor> <dc:creator>Schneider, Achim</dc:creator> <dc:contributor>Öhlschläger, Peter</dc:contributor> <dc:contributor>Osen, Wolfram</dc:contributor> <dc:language>eng</dc:language> <dc:contributor>Schneider, Achim</dc:contributor> <dc:creator>Kaufmann, Andreas M.</dc:creator> <dc:creator>Öhlschläger, Peter</dc:creator> <dc:creator>Gissmann, Lutz</dc:creator> <dc:contributor>Kaufmann, Andreas M.</dc:contributor> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dcterms:bibliographicCitation>Publ. in: Vaccine ; 24 (2006), 15. - pp. 2880-2893</dcterms:bibliographicCitation> <dc:creator>Dürst, Matthias</dc:creator> <dc:creator>Osen, Wolfram</dc:creator> <dcterms:rights rdf:resource="http://nbn-resolving.org/urn:nbn:de:bsz:352-20140905103605204-4002607-1"/> <dcterms:issued>2006-04-05</dcterms:issued> <dc:contributor>Pes, Michaela</dc:contributor> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dcterms:abstract xml:lang="eng">A new and very promising approach in vaccine development is the application of naked DNA. In comparison to conventional vaccines it offers several advantages, especially if there is a need for the development of low cost vaccines. Infection with high-risk human papillomaviruses (hr-HPVs) is the major risk factor for the development of cervical cancer (cc), the third most common cancer in women worldwide. The HPV E7 oncogene is constitutively expressed in HPV-infected cells and represents an excellent target for immune therapy of HPV-related disease. Therefore, we chose the HPV-16 E7 as model antigen in the development of a therapeutic DNA vaccine candidate. For safety reasons the use of a transforming gene like the HPV-16 E7 for DNA vaccination is not feasible in humans. In consequence we have generated an artificial (“shuffled”) HPV-16 E7-gene (HPV-16 E7SH), containing all putative cytotoxic T-lymphocyte (CTLs) epitopes and exhibiting high safety features. Here, we show the induction of a strong E7-wildtype (E7WT) directed cellular and humoral immune response including tumor protection and regression after in vivo immunization in the murine system. Moreover, the vaccine candidate demonstrated immunogenicity in humans, demonstrated by priming of antigen-specific T cells in vitro. Importantly, the artificial HPV-gene has completely lost its transforming properties as measured in soft agar transformation assays. These results may be of importance for the development of vaccines based on oncogenes or oncoproteins.</dcterms:abstract> </rdf:Description> </rdf:RDF>

Das Dokument erscheint in:

KOPS Suche


Stöbern

Mein Benutzerkonto